SG40895A1 - Propiophenone derivative and processes for preparing the same - Google Patents

Propiophenone derivative and processes for preparing the same

Info

Publication number
SG40895A1
SG40895A1 SG1996010897A SG1996010897A SG40895A1 SG 40895 A1 SG40895 A1 SG 40895A1 SG 1996010897 A SG1996010897 A SG 1996010897A SG 1996010897 A SG1996010897 A SG 1996010897A SG 40895 A1 SG40895 A1 SG 40895A1
Authority
SG
Singapore
Prior art keywords
preparing
processes
same
propiophenone derivative
hydrogen atom
Prior art date
Application number
SG1996010897A
Other languages
English (en)
Inventor
Kenji Tsujihara
Kunio Saito
Mamoru Matsumoto
Kozo Oka
Mitsuya Hongu
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of SG40895A1 publication Critical patent/SG40895A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG1996010897A 1995-11-07 1996-10-22 Propiophenone derivative and processes for preparing the same SG40895A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7288487A JP3059088B2 (ja) 1995-11-07 1995-11-07 プロピオフェノン誘導体およびその製法

Publications (1)

Publication Number Publication Date
SG40895A1 true SG40895A1 (en) 1997-06-14

Family

ID=17730854

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996010897A SG40895A1 (en) 1995-11-07 1996-10-22 Propiophenone derivative and processes for preparing the same

Country Status (12)

Country Link
US (1) US5767094A (da)
EP (1) EP0773226B1 (da)
JP (1) JP3059088B2 (da)
KR (1) KR100333572B1 (da)
CN (1) CN1049222C (da)
AT (1) ATE175676T1 (da)
CA (1) CA2189603C (da)
DE (1) DE69601345T2 (da)
DK (1) DK0773226T3 (da)
ES (1) ES2128137T3 (da)
SG (1) SG40895A1 (da)
TW (1) TW460477B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406086B (en) * 1996-12-26 2000-09-21 Tanabe Seiyaku Co Propiophenone derivatives and process for preparing the same
AU5755200A (en) 1999-08-27 2001-03-26 Joel R.L. Ehrenkranz Method of using dihydrochalcone derivatives to block glucose transfer
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4590158B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
RS20060320A (en) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
EA011515B1 (ru) * 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EP1680131A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDOLE-O-GLUCOSIDES
TWI385177B (zh) * 2003-08-01 2013-02-11 Mitsubishi Tanabe Pharma Corp 吡喃葡萄糖基衍生物及其製造方法
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
AR048376A1 (es) * 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv C- glicosidos heterociclos fusionados sustituidos
FR2862303B1 (fr) * 2003-11-17 2006-01-06 Agronomique Inst Nat Rech Preparations colorantes hydrosolubles jaunes derivees des dihydrochalcones, leur procede des preparation, et leurs utilisations
TWI332707B (en) 2005-08-04 2010-11-01 Au Optronics Corp Array substrate of a liquid crystal display and method of fabricating the same
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
EA020209B1 (ru) * 2007-09-10 2014-09-30 Янссен Фармацевтика Н.В. Способ получения соединений, применимых в качестве ингибиторов натрийзависимого переносчика глюкозы
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
BRPI0913129A2 (pt) 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PT2451797E (pt) 2009-07-10 2013-06-25 Janssen Pharmaceutica Nv Processo de cristalização para o 1-(β-d-glucopiranosilo)-4-metilo-3-[5-(4-fluorofenilo)-2-tienilometilo]benzeno
SG10201500258WA (en) * 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
KR101913587B1 (ko) 2011-04-13 2018-10-31 얀센 파마슈티카 엔.브이. Sglt2의 억제제로서 유용한 화합물의 제조 방법
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
SG11202100417RA (en) 2018-07-19 2021-02-25 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
AU2022251165A1 (en) 2021-04-01 2023-11-09 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same

Also Published As

Publication number Publication date
MX9605415A (es) 1997-10-31
ATE175676T1 (de) 1999-01-15
JPH09124686A (ja) 1997-05-13
CN1049222C (zh) 2000-02-09
CN1151405A (zh) 1997-06-11
DE69601345T2 (de) 1999-06-17
TW460477B (en) 2001-10-21
KR970027098A (ko) 1997-06-24
DK0773226T3 (da) 1999-08-30
US5767094A (en) 1998-06-16
CA2189603A1 (en) 1997-05-08
DE69601345D1 (de) 1999-02-25
KR100333572B1 (ko) 2002-09-18
ES2128137T3 (es) 1999-05-01
EP0773226A1 (en) 1997-05-14
CA2189603C (en) 2003-06-10
JP3059088B2 (ja) 2000-07-04
EP0773226B1 (en) 1999-01-13

Similar Documents

Publication Publication Date Title
SG40895A1 (en) Propiophenone derivative and processes for preparing the same
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
AU5752194A (en) Benzimidazole compounds, their use and preparation
HU9600834D0 (en) Quinazoline derivatives
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
IL148384A0 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
GR3001362T3 (en) Quinazolinone derivative and processes for preparing the same
IE892340L (en) 4-oxoquinoline-3-carboxylic acid derivatives, their¹preparation and their use
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
AU8156394A (en) Methods for inhibiting LDL oxidation and atheroclerosis
IE883003L (en) Pyridine derivatives and related intermediates
AU2722095A (en) Novel pyrrolocarbazoles
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
AU7149794A (en) Phenylalkanolamine derivatives
CA2065799A1 (en) Thiazolidinedione derivatives, their production and their use
HK1031867A1 (en) 2-phenoxyaniline derivatives
EP1034783A4 (en) AMIDE DERIVATIVES
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
CA2204204A1 (en) Carbohydrate derivatives
HUT50354A (en) Process for producing new s-adenosylmethionine decarboxilase inhibitors
AU2002214325A1 (en) Process for producing carbapenem-type antibacterial
GB9420747D0 (en) 1,5 benzodiazepine derivatives
EP0855398A4 (en) SESQUITERPEN DERIVATIVES WITH ANTIVITAL ACTIVITY
AU7441794A (en) Composition for prophylaxis and treatment of myopia
AU639875B2 (en) 5-amino-5,6,7,8-tetrahydroquinolines and related compounds and pharmaceutical use